Neuphoria Therapeutics (NEUP) Price to Sales (2025)
Neuphoria Therapeutics' Price to Sales came in at 461.09 for FY2026 (year ended Jun 30, 2026), up 720.3% from 56.21 in FY2025.
Powered by 
Analysis
Neuphoria Therapeutics (NEUP) Price to Sales (2025) Analysis & Trends
Going back to FY2022, Neuphoria Therapeutics' Price to Sales data covers 4 fiscal years.
- The FY2026 figure represents the highest annual Price to Sales since FY2023.
- Per Business Quant, earlier fiscal years put Price to Sales at 56.21 in FY2025, 221962.06 in FY2023 (+343.1%) and 50094.84 in FY2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn |
| 10 | Neuphoria Therapeutics | 335.34 Mn | 260.15 Mn | - |
API Access
Neuphoria Therapeutics Price to Sales API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=price-to-sales&ticker=NEUP&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "price-to-sales", "ticker": "NEUP", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=price-to-sales&ticker=NEUP&period=max&api_key=YOUR_API_KEY");
const data = await res.json();